Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza

Background New prophylactic and therapeutic strategies to combat human infections with highly pathogenic avian influenza (HPAI) H5N1 viruses are needed. We generated neutralizing anti-H5N1 human monoclonal antibodies (mAbs) and tested their efficacy for prophylaxis and therapy in a murine model of infection. Methods and Findings Using Epstein-Barr virus we immortalized memory B cells from Vietnamese adults who had recovered from infections with HPAI H5N1 viruses. Supernatants from B cell lines were screened in a virus neutralization assay. B cell lines secreting neutralizing antibodies were cloned and the mAbs purified. The cross-reactivity of these antibodies for different strains of H5N1 was tested in vitro by neutralization assays, and their prophylactic and therapeutic efficacy in vivo was tested in mice. In vitro, mAbs FLA3.14 and FLD20.19 neutralized both Clade I and Clade II H5N1 viruses, whilst FLA5.10 and FLD21.140 neutralized Clade I viruses only. In vivo, FLA3.14 and FLA5.10 conferred protection from lethality in mice challenged with A/Vietnam/1203/04 (H5N1) in a dose-dependent manner. mAb prophylaxis provided a statistically significant reduction in pulmonary virus titer, reduced associated inflammation in the lungs, and restricted extrapulmonary dissemination of the virus. Therapeutic doses of FLA3.14, FLA5.10, FLD20.19, and FLD21.140 provided robust protection from lethality at least up to 72 h postinfection with A/Vietnam/1203/04 (H5N1). mAbs FLA3.14, FLD21.140 and FLD20.19, but not FLA5.10, were also therapeutically active in vivo against the Clade II virus A/Indonesia/5/2005 (H5N1). Conclusions These studies provide proof of concept that fully human mAbs with neutralizing activity can be rapidly generated from the peripheral blood of convalescent patients and that these mAbs are effective for the prevention and treatment of H5N1 infection in a mouse model. A panel of neutralizing, cross-reactive mAbs might be useful for prophylaxis or adjunctive treatment of human cases of H5N1 influenza.

[1]  J. Dai,et al.  OL-043 Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice , 2009 .

[2]  R. Fouchier.  Faculty Opinions recommendation of Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. , 2007 .

[3]  S. Hoffman,et al.  Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? , 2006, Annals of Internal Medicine.

[4]  R. Webby,et al.  Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice , 2006, Respiratory research.

[5]  Yi Guan,et al.  Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia , 2006, Nature Medicine.

[6]  K. Mozdzanowska,et al.  Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. , 2006, Virology.

[7]  Mark Wolff,et al.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. , 2006, The New England journal of medicine.

[8]  Zhong-min Guo,et al.  Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice , 2006, Respiratory research.

[9]  Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. , 2006, Releve epidemiologique hebdomadaire.

[10]  Yi Guan,et al.  Oseltamivir resistance during treatment of influenza A (H5N1) infection. , 2005, The New England journal of medicine.

[11]  Hideo Goto,et al.  Avian flu: Isolation of drug-resistant H5N1 virus , 2005, Nature.

[12]  Keiji Fukuda,et al.  Evolution of H5N1 Avian Influenza Viruses in Asia , 2005, Emerging infectious diseases.

[13]  Angus Nicoll,et al.  Avian influenza A (H5N1) infection in humans. , 2005, The New England journal of medicine.

[14]  Prasert Auewarakul,et al.  Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. , 2005, The Journal of general virology.

[15]  P. Wright,et al.  Role of IgA versus IgG in the Control of Influenza Viral Infection in the Murine Respiratory Tract1 , 2004, The Journal of Immunology.

[16]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[17]  Y. Guan,et al.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia , 2004, Nature.

[18]  Constance Schultsz,et al.  Avian influenza A (H5N1) in 10 patients in Vietnam. , 2004, The New England journal of medicine.

[19]  K. Mozdzanowska,et al.  Complement Component C1q Enhances the Biological Activity of Influenza Virus Hemagglutinin-Specific Antibodies Depending on Their Fine Antigen Specificity and Heavy-Chain Isotype , 2002, Journal of Virology.

[20]  A. Osterhaus,et al.  Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region , 2000, Archives of Virology.

[21]  L. Sawyer.  Antibodies for the prevention and treatment of viral diseases. , 2000, Antiviral research.

[22]  N. Cox,et al.  A Mouse Model for the Evaluation of Pathogenesis and Immunity to Influenza A (H5N1) Viruses Isolated from Humans , 1999, Journal of Virology.

[23]  H. Goto,et al.  Biological Heterogeneity, Including Systemic Replication in Mice, of H5N1 Influenza A Virus Isolates from Humans in Hong Kong , 1999, Journal of Virology.

[24]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[25]  K. Mozdzanowska,et al.  Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice , 1995, Journal of virology.

[26]  I. Wilson,et al.  Structural basis of immune recognition of influenza virus hemagglutinin. , 1990, Annual review of immunology.

[27]  C. Sweet,et al.  Role of milk-derived IgG in passive maternal protection of neonatal ferrets against influenza. , 1987, The Journal of general virology.

[28]  C. Sweet,et al.  Production of passive immunity in neonatal ferrets following maternal vaccination with killed influenza A virus vaccines. , 1987, Immunology.

[29]  E. Ayoub,et al.  Maternal-infant transfer of influenza-specific immunity in the mouse. , 1983, Journal of immunology.

[30]  I. Wilson,et al.  Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation , 1981, Nature.

[31]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[32]  J. Puck,et al.  Protection of infants from infection with influenza A virus by transplacentally acquired antibody. , 1980, The Journal of infectious diseases.